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Background: Current genetic test algorithms for Charcot Marie Tooth (CMT) disease are based on family details
and comprehensive clinical and neurophysiological data gathered under ideal conditions for clinical assessment.
However, in a diagnostic laboratory setting relying on external test requisitions and patient samples, such
conditions are not always met. Our objective was therefore to perform a retrospective evaluation of the data given
in laboratory request forms and to assess their quality and applicability with regard to the recommended
algorithms for CMT diagnostics. As we are the main test centre for CMT in Norway our results also provide an
overview of the spectrum of gene defects in the Norwegian CMT population.
Methods: Genetic testing was performed according to polyneuropathy type; demyelinating/mixed: PMP22
duplication, MPZ, EGR2, LITAF, NEFL, PMP22, GJB1, axonal: MFN2, MPZ, NEFL, and GJB1.
Results: Diagnostic testing of index patients was requested in 435 of the 549 cases. Seventy-two (16.6%) positive
molecular genetic findings were made. The majority (94.6%) of mutation positive cases showed disease onset
before 50 years of age. PMP22 (duplication), MPZ, GJB1 and MFN2 mutations constituted 95.8% of the positive
findings. Within the nerve conduction study groups, mutation detection rates were; demyelinating 33.8%; mixed
29.0%; axonal 8.8%; unspecified 16.5%.
Conclusion: We suggest a simplified algorithm intended for referral centres, dealing with DNA/blood samples,
which involves the assessment of age at onset and neurophysiological data followed by testing of four genes;
PMP22 (duplication), MPZ, GJB1 and MFN2. Patients negative for mutations in those four genes should be subjected
to evaluation at an interdisciplinary inherited neuropathy clinic with the capacity for extended molecular genetic
analysis by next generation sequencing.
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Charcot Marie Tooth disease (CMT) is the most pre-
valent hereditary neuropathy [1]. In the population of
Western-Norway the prevalence has been estimated to
41:100000 [2].
The classic clinical picture of Charcot Marie Tooth
disease is characterized by muscular atrophy and weak-
ness in the distal parts of the legs, absence of Achilles
tendon reflexes, pes cavus, hammertoes and loss of
touch and vibratory sensation. Nerve Conduction Ve-
locity (NCV) in the motor median nerve is used to div-
ide autosomal dominant CMT into CMT1 (<38 m/s),
CMT2 (>38 m/s) [3] and dominant intermediate CMT
(25–45 m/s) [4]. Autosomal recessive CMT is called
CMT4 and X-linked CMT CMTX independent of the
NCV. Subtypes are defined by the mutant gene and
more than 40 CMT associated genetic loci have been
identified [5]. The most common CMT subtypes are
CMT1A due to a PMP22 duplication (70–80% of the
CMT1 cases) [6,7], CMT2A2 caused by MFN2 muta-
tions (10–30% of the CMT2 cases) [8,9], CMTX1
(GJB1) [4] and CMT4A (GDAP1). Atypical clinical pre-
sentations are well documented, particularly for CMT2
[10], CMT4, and CMTX [6]. The recessive CMT4 is as-
sociated with an early onset and severe symptoms.
Due to the clinical and genetic heterogeneity, the low
sensitivity of genetic testing for CMT2 and scarcity of
clinical data, CMT as a group represents a number of
challenges for diagnostic laboratories. Recommended
algorithms for CMT testing relies on exact clinical de-
tails, results from nerve conduction studies (NCS) and
inheritance patterns gathered under ideal conditions
[11,12] and are therefore suited for specialized neuro-
muscular or inherited polyneuropathy clinics. Such con-
ditions, however, rarely reflect the reality in everyday
practice in laboratories dealing with samples from exter-
nal patients and, thus, the yield of positive genetic test
results in this group is significantly lower [13]. In
Norway the vast majority of patients are being tested in
this context and, likewise, in a recent UK study [13]
almost 2/3rds of investigations were performed on CMT
samples from external patients, demonstrating that this
is not only a Norwegian phenomenon. In spite of the
different test situations and the more heterogeneous
nature of the latter group, in depth studies of the diag-
nostic efficacy of genetic testing of samples sent from
external requisitioners are lacking. With regards to
guidelines for testing, however, the two groups are often
treated as if they were the same. Therefore, our main
objective was to assess the quality and applicability of
the recommended algorithms for CMT diagnostics in
the diagnostic laboratory context. We have reviewed 559
requests for CMT testing received during the period
from year 2004 to 2010. We aimed at investigating towhich extent available clinical and family information is
influencing the success in the identification of disease
causing variants. Based on these results we suggest a
strategy for molecular genetic CMT testing for diagnos-
tic laboratories which will provide an increase in conclu-
sive test results, a decrease in false positive results and a
more efficient use of resources. Furthermore, the results
presented here may be of assistance in delineating the
patient group that requires the services of an interdiscip-
linary inherited neuropathy clinic that have the capacity
of detailed clinical and neurophysiological studies by
experienced clinicians, and also extended molecular
genetic analysis by next generation sequencing (NGS).
Methods
Patient population
The Department of Medical Genetics University Hospital
of North-Norway is a part of the National Neuromuscular
Centre and serves as a referral centre for genetic testing of
patients with neuromuscular disorders from all parts of
Norway. The annual number of samples received from
patients with suspected CMT increased steadily from 25
in 2004 to 147 in 2010; accumulating at a total number of
559 for the seven-year period. Diagnostic, carrier or pre-
dictive, testing for known family mutations were requested
for 87 patients. These results are not included in this
work. Male-to-female ratio in the remaining 472 cases
was 1.4:1, and mean age 47.4 (±21.7) years. Based on the
information received in the laboratory request forms,
37 requests were rejected. Figure 1A shows the annual
sample count and the proportion of rejected samples. The
test algorithm was shortened with one or more of the
requested analyses in 137/435 investigated index cases. An
average of 2.7 genes pro sample were tested in those cases
(Additional file 1: Table S1). The rejected group and those
with deviation from the test protocol lacked information
about nerve conduction studies (NCS) and had sparse or
irrelevant clinical information.
Genetic analyses
DNA was extracted from peripheral blood cells using a
Genovision M48 (Qiagen) or Biorobot EZ-1 (Qiagen)
systems. Patients with demyelinating polyneuropathy were
screened with a CMT1 test battery containing Multiplex
Ligation dependent Probe Amplification (MLPA) of the
PMP22 region for the assessment of quantitative alte-
rations and by DNA sequencing of the MPZ, EGR2,
LITAF, NEFL, PMP22 and GJB1 coding exons including at
least 20 nt of each flanking intron sequence. Cases with
nerve conduction velocities in the intermediate range or
with mixed polyneuropathy were also screened with the
CMT1 test battery. Patients with axonal polyneuropathy
were investigated using a CMT2 test battery which in-
cluded DNA sequencing of the MFN2, MPZ, NEFL and
Figure 1 (See legend on next page.)
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Figure 1 Recruitment of patient samples, patterns of inheritance, clinical details and genetic findings among the CMT patients. (A) The
annual number of rejected and analyzed samples, 472 in total. Blue color; analyzed in accordance with protocol; green color; analyzed, but with
deviation from protocol. (B) The sample count and number of findings in the individual clinical groups. 1; Polyneuropathy/CMT? No further
information. 2; Specified symptoms of classical CMT. 3; As 2, but specified as severe. 4; As 2, but also with hearing impairment/deafness, pyramidal
features, fasciculation, tremor, white matter changes on MRI. 5 Specified symptoms of atypical CMT (Additional file 1: Table S3). 6; Polyneuropathy
as part of a more complex clinical picture with additional features usually not seen in association with CMT. 9; Requesting physician primarily
suspects alternative diagnosis. (C) The sample count and number of findings in relation to mode of inheritance. (D) The patterns of inheritance in
relation to genetic findings. (E) The NCS results in relation to pattern of inheritance.
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flanking intron sequence. The group of patients displaying
normal NCS results was analysed with the CMT2 test
panel. Cases, in whom the polyneuropathy type could not
be specified, were classified as “deviation from test pro-
tocol” if they were not analyzed with both the CMT1 and
CMT2 panel. Based on clinical and family information,
the GDAP1 gene was sequenced in individual cases
(58/435) representing all polyneuropathy groups. MPZ/
MFN2 MLPA was performed on 229/435 samples.
The primers used for PCR amplification and DNA se-
quencing are listed in the Additional file 1: Table S2.
MLPA reactions were performed using MLPA kits
(MRC Holland, Amsterdam, The Netherlands), and PCR
products were analyzed by fragment analysis using the
Applied Biosystems 3130xl Genetic Analyzer. For CMT1A
testing we used the SALSA MLPA KIT P033-B2 CMT1
and for the CMT1A/CMT2A2 testing SALSA MLPA
P143 MFN2-MPZ probemix (further details are available
upon request). Genetic variants were evaluated using the
Alamut software (Interactive Biosoftware, San Diego, CA,
USA) and in depth literature studies. The variants were
categorized into five classes in accordance with the
recommendations from the IARC Unclassified Genetic
Variants Working Group [14]. Positive findings were
defined as uncertain, probable or definite cause of the
disease. Variants interpreted as non-pathogenic or likely
non-pathogenic were defined as negative findings.
Data collection, statistics and endpoint measures
From the requisitions the following data were collected
and systematized: The year the sample was received, the
indication for testing (diagnostic, carrier/predictive or
testing rejected), the specialty of the requesting phy-
sician (neurology, medical genetics, pediatrics, other),
the age at onset of symptoms, the age at testing, whether
or not supplemental information had been requested, re-
sults from motor NCV in the median nerve, whether or
not there were deviations from the test algorithm, if
CMT1A had been excluded previously at another la-
boratory, the type of polyneuropathy as indicated by
NCS, the pattern of inheritance and a description of the
family history, the number of affected relatives reportedin addition to the index case, the gender of the index pa-
tient and their relatives, whether or not the mutation
was found, and if yes, the name of the gene/mutation
and the interpretation of its consequences (from 5 to 1,
Additional file 1: Table S3).
To investigate to which extent available clinical informa-
tion is influencing the success of genetic diagnostics we
found it necessary to stratify our patient population in 9
clinical categories as follows; 1: polyneuropathy/CMT − no
further information; 2: Symptoms of classical CMT speci-
fied; 3: as 2, but more severe; 4: as 2, but with additional
hearing impairment, pyramidal features, fasciculations,
tremor or white matter changes on MRI; 5: Symptoms
of atypical CMT, HSAN or HMN specified; 6: poly-
neuropathy with additional features not usually seen in
association with CMT (typically ptosis, dysmorphic/multi-
systemic features); 7: healthy; 8: testing with regards to a
family mutation, symptoms not specified; 9: requesting
physician primarily suspects alternative diagnosis (CIDP,
congenital myopathy, etc.). Further details, for each cat-
egory, are shown in Additional file 1: Table S3.
Data from the individual categories were analyzed and
data from the two patient groups, the mutation positive
and the mutation negative, were compared. Statistical
Package for the Social Sciences (SPSS) version 20.0 was
used for the statistical analyses.
The research protocol was approved by the Regional
Committee for Medical and Health Research Ethics for
the counties of Nordland, Troms and Finnmark (REK
Nord), and by the Norwegian Data Inspectorate. REK
Nord specified that informed consent given by subjects/
next-of-kin was not necessary for this study. Procedures
were in accordance with the 1964 Declaration of Helsinki
and its later amendments.
Results
Clinical information and mutation detection rate
Among the 435 cases tested, 72 (16.6%) were found to
be mutation positive. They all belonged to the clinical
groups 1–4 (Figure 1B). The 73 cases belonging to cli-
nical group 5, 6 and 9 were all mutation negative. This
difference in detection frequency between groups 1–4
and 5–9 is highly significant (Pearson chi-square 0.000).




Disease causing mutation Total
countFound Not found




Axonal 17 176 193
8,8% 91,2%
Mixed 12 29 41
29,3% 70,7%
Not specified 16 81 97
16,5% 83,5%
Normal 0 11 11
0% 100,0%
Total 72 363 435
16,6% 83,4%
In 59 cases CMT1A had already been excluded at other laboratories. The
results reported in brackets concern the demyelinating group excluding these
cases. The NCS-normal group was analyzed with the CMT2 test panel.
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followed by group 2 (25.7%), group 1 (15.7%) and group 3
(7.1%). The patients in the clinical group 4 had PMP22
duplications (4), point mutations in MPZ (2), NEFL (1),
GJB1 (1) and a deletion of exon 13–17 in MFN2.
Patterns of inheritance
Inheritance patterns reported in the 435 cases were
autosomal dominant (33.6%), family history not specified
(28.5%), single case (20.0%), X-linked (7.8%), autosomal
recessive (5.5%) and positive, but with unspecified family
history (4.6%). Among the 72 cases with a positive
genetic test result, information on family history was
reported in 66.6%. In the 363 cases with a negative test
result, 48.5% had a positive family history (Pearson chi
square p = 0.005). Positive test results were made in all
groups with the highest yield in the group with positive,
but unspecified family history (35.0%), followed by the
autosomal dominant (21.9%), X-linked (20.6%), single case
(12.6%), family history not specified (10.5%) and auto-
somal recessive group (8.3%) (Figure 1C). Seven of the pa-
tients with a positive test result had a suspected X-linked
inheritance and 6 of these also had a mutation in the
GJB1 gene (Figure 1D). Among 32 patients from families
with a suspected dominant inheritance, but with no docu-
mented male to male transmission, 11 tested positive on
mutations in the GJB1 gene. The two positive findings in
the recessive group were “dominant mutations” in the
MPZ gene, but no “recessive mutations” were identified.
Among 26 cases with PMP22 duplication, only 10 had
been assigned as dominant inheritance. In comparison,
55.0% (11) of the patients with a GJB1 mutation had been
suspected to come from families where CMT segregated
as a dominant trait. In 231/435 samples information about
the inheritance could not be used to specify CMT subtype
because they were either single cases or positive, but with
unspecified or unavailable family history. In addition,
47 cases with suspected autosomal dominant, X-linked
and recessive inheritance, lacked results of Nerve Con-
duction Studies (NCS) (Figure 1E).
Description of the family history
The number of affected relatives was reported for 199
cases. Among 43 patients with a positive genetic test result
the mean number of relatives specified was 2.14 ± 1.28.
Among 156 patients with a negative genetic test result the
mean number of relatives specified was 1.78 ± 0.97.
Among the same 199 cases the gender of index and rela-
tives were male and female in 119 cases (59.8%), male only
in 53 (26.6%) and female only in 27 cases (13.6%).
Nerve conduction studies
Polyneuropathy was reported as demyelinating in 21.4%,
axonal in 44.4%, mixed in 9.4%, not specified in 22.3%,and normal in 2.5%. The demyelinating and mixed poly-
neuropathy groups were analyzed with the same testing
panel and showed equivalent mutation detection rates
(33.8%; 29.3%), (Table 1). Patients, for whom NCS re-
sults suggested axonal neuropathy, constituted the lar-
gest group and showed the lowest detection rate (8.8%).
For patients with NCS-unspecified we obtained a detec-
tion rate of 16.5%, similar to the rate found in the mate-
rial as a whole (16.6%). CMT1A had already been
excluded at other laboratories in 59 cases. The mutation
detection rate among these 59 cases was 22.0% (3 MPZ,
1 NEFL, 7 GJB1 and 2 MFN2 mutations). The distribu-
tion of mutant genes within the NCS groups is similar
to what has been reported in the literature. Independent
of gender, patients with GJB1 mutations are represented
in all polyneuropathy groups with the majority, however,
in the mixed category.
Age at disease onset and age at testing
Figure 2A shows the bimodal distribution of age at tes-
ting in the group of 435 patients with a second peak
starting at 40 years. The age distribution among the
NCS groups at testing shows an early peak in the de-
myelinating group and a late peak in the axonal group,
but also in the unspecified group (Figure 2B). Among
the 72 cases with a positive genetic test result, the mean
age at testing was 37.6 ± 19.4 years, and among the cases
with a negative test result it was 48.9 ± 21.6 years. Al-
most half of the samples received (231/435) were from
patients older than 50 years and 23 positive test results
Figure 2 (See legend on next page.)
Østern et al. BMC Medical Genetics 2013, 14:94 Page 6 of 11
http://www.biomedcentral.com/1471-2350/14/94
(See figure on previous page.)
Figure 2 Clinical, NCS and genetic findings among the CMT patients. (A) Histogram; the age at testing in 435 patients. (B) The distribution
of age at testing within the NCS groups. (C) Boxplot: the relationship between age at onset and age at testing in 229 samples. (D) The
distribution of age at disease onset (229 cases) in the group with positive (blue) and negative (green) findings. (E) The relative frequency of
genetic findings. (F) The distribution of genetic findings and interpretation of disease association for 72 mutations.
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detection yield obtained in the groups younger versus
older than 50 years at testing is significant (Pearson chi-
square 0.000), the association between age at onset and
age at testing is loose (Figure 2C).
Age of onset was reported for 229/435 cases (52.6%).
Among these, 37 (16.6%) were found to be positive on
genetic testing. Figure 2D compares the age at disease
onset in the groups with a positive and negative test re-
sult. Most positive findings were made in patients with
onset age < 30 years (78.3%) and the highest frequency
was associated with onset between 5–20 years (56.7%).
The remaining fraction (21.7%) of the positive findings
was made in patients with reported onset between 30
and 60 years. However, in the patient material as a
whole, 94.6% of the mutation positive patients showed
disease onset before 50 years of age. Two mutations
were found in the group with onset between 50 and
60 years: a duplication of the PMP22 region and a mis-
sense mutation of uncertain significance (p.Asp35Asn)
in the MPZ gene.
Medical specialties and requisitioning
Only index cases were included in this work. All 472
molecular genetic tests were requested by medical
doctors. The vast majority was requested from neu-
rology departments (77.1%), but also from departments
of medical genetics (7.4%) and pediatrics (10.8%). TheTable 2 Novel sequence variants not reported in the HGMDp
Gene cDNA Protein
MPZ c.679 A > T p.Arg227*
c.368 G > T p.Gly123Val




c.250 A > G p.Lys84Glu
c.612 T > A p.Asp204Glu
c.653 T > C p.Leu218Pro
c.692 C > T p.Ser231Phe
c.1921 T > C p.Tyr641His
†HGMDp version 2013.2.
$het = heterozygous; homo = homozygous; hemi = hemizygous.
£Classification of genetic variants in accordance with the recommendations from th
causing, 3 = variant of uncertain significance.remaining 4.7% of the test requests came from medical
doctors belonging to other fields of medicine, mostly
primary care. Medical genetic departments and “other”
often cooperated with a neurologist or pediatrician when
they requested testing. Due to sparse clinical informa-
tion, supplementary information was asked for in 157
cases prior to the selection of testing strategy. The
response rate was 61.8% (97/157). The additional infor-
mation received was not always relevant, particularly
when the questions were concerning NCS.
Molecular genetic findings
Figure 2E shows the relative proportion of positive test
results for the various genes tested. The genetic variants
detected were interpreted as definitely disease causing in
48, likely disease causing in 12 and uncertain in 12 cases
(Figure 2F). Novel mutations not listed in The Human
Gene Mutation Database Professional (HGMDp) (www.
biobase-international.com) version 2013.2, are listed in
Table 2. Genetic variants interpreted as likely not, or
definitely not disease causing are not dealt with in the
present article. The majority (95.8%, 69/72) of the posi-
tive molecular genetic findings were either duplication
of the PMP22 region or sequence variants in either one
of the MPZ, GJB1 or MFN2 genes. Testing with MPZ/
MFN2 MLPA was performed on 229 samples from
all NCS groups and there was one positive finding (de-





In-frame deletion het 3
Deletion hemi 4






e IARC Unclassified Genetic Variants Working Group [14]; 4 = probably disease
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sequence variants of uncertain significance in the NEFL
gene. Among the 116 cases analysed with regard to
LITAF/SIMPLE and EGR2 mutations, and among the
196 cases sequenced with regards to PMP22 point muta-
tions, no disease causing mutations were found.Discussion
All positive genetic test results were made on samples
belonging to the clinical groups 1–4, displaying the clas-
sical symptoms of CMT. Almost half of these were
detected in clinical group 1 in which there were sparse,
but relevant, clinical information. No disease causing
mutations were found in patients for whom the clinical
information gave reason to suspect atypical CMT2, or al-
ternative diagnoses like hereditary sensory and autonomic
neuropathy (HSAN), hereditary motor neuronopathy
(HMN) or polyneuropathy as part of a more complex
clinical picture. The low detection yield in clinical group 3
and in those with a recessive family history, as well as the
absence of GDAP1 mutations in 58 selected patients,
imply that we still know little about the genetics of severe/
recessive CMT in Norway. None of the patients with a
MFN2 mutation had optic atrophy nor were they cate-
gorized as very severely affected.Table 3 Mutation detection rates associated with suspected H
Population N total Demyelinating/mixed polyneuropathy (CMT1,
N (%)
PMP22(dup) MPZ EGR2 LITAF
Spanish [15] 47 35 excl 8.6 - -
Korean [16] 57 32 46,9 3.1 3.1 -
Italian [17] 172 170 57.6 2.4 0 -
Australian [18] 224 224£ 60.7 3.1 - -
Finnish [19] 58 23 excl 13.0 - -
Japanese [20] 354 227 23.3 8.8 0.4 0
British [21] 775 443 28.2 4.2 3.3 -
American [6] 153 145 51.6 3.4 0.7 -
Russian [22] 174 108 53.7 4.6 - -
European [9] 323 26 - - - -
American [8] 13 0 - - - -
American [23] 39 1 - - - -
Average 2389 1407 41.8 5.0 0.5 0
This study 435 134 18.7‡ 6.0 0 0
The analyses were performed at referral centres for external patients (prospective t





‡20/107, in 27 cases CMT1A were excluded at another laboratory.We find that although a positive family history is asso-
ciated with an increased probability of positive test
results, the apparent pattern of inheritance is of limited
value in the selection of testing strategy in most cases.
The exceptions are cases with documented male-to-male
transmission, leaving GJB1 testing redundant, as well as
for cases where family history suggests a recessive inhe-
ritance, indicating that a causative mutation(s) is likely
to be found outside the four common genes. However,
the family history and subsequent segregation studies
are very useful in evaluating genetic variants of unknown
or doubtful significance.
Notably, in this study 63.9% of the cases could not be
classified in accordance with CMT subtype definitions as
they were single cases, cases with positive but unspeci-
fied family history, cases where family history was not
mentioned, or more rarely because they lacked suitable
NCS results.
The reported frequency of PMP22 duplication in index
patients with suspected CMT1 ranges between 23.3%
and 60.7% (average 41.8%) across different studies, and
in different populations (Table 3) [8,9,15-23]. The re-
ported frequency of MPZ mutations ranges between
2.4% and 13.0% (average 5.0%) and GJB1 mutations bet-
ween 5.5% and 25.8% (average 8.8%) (Table 3). The
mutation detection yields reported in different studiesMSN in various populations
DSS†, CHN$) Axonal polyneuropathy (CMT2)
N (%)
NEFL PMP22 GJB1 MFN2 NEFL MPZ GJB1
- 2.9 17.1 7 - - 0 57.1
3.1 3.1 6.2 18 - 5.6 11.1 5.6
- 1.2 7.1 0 - - - -
- 1.3 12.1 0 - - - -
- 4.3 13.0 29 - - 0 24.1
3.5 4.4 8.4 127 11.3 0 3.9 4.7
9.5 5.3 25.8 NR 13.6 - 4.6 2.7
0 3.4 5.5* 7 - 14.3 0 42.9
- 1.9 7.4 32 - - 0 3.1
- - - 249 11.2 - - -
- - - 13 23.1 - - -
- - - 38 17,9 - - -
2.2 2.6 8.8 520 12.2 1.3 3.2 10.0
0.7 0 6.7 193 5.7 0.5 1.0 1.5
esting of index cases). The discrepancy between N total and N CMT1/CMT2 are
le.
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sampling methods, testing strategies and ways of reporting
the results. Also, most reports only give a detailed descrip-
tion of patients with positive test results, not the entire
cohort. The frequency of PMP22 duplications among the
demyelinating polyneuropathy patients in this material
was lower than average (18.7%), whereas the frequency of
MPZ mutations (6.0%) and GJB1 mutations (6.7%) were
close to average. This may indicate that PMP22 duplica-
tions are less frequent or that a large part of the families
with PMP22 duplication in Norway already were identified
by other laboratories before the start of our observation
period. Also, a prior exclusion of CMT1A might have
been underreported in the patient request forms. A pre-
vious study, however, estimated a similar frequency of the
PMP22 duplication (13.6%) in families with CMT in a
population in Southern Norway (inhabitants of Akershus
County) [24]. The rate of positive molecular diagnostic
findings in CMT patients attending neuropathy clinics,
compared to external samples sent for molecular genetic
investigation, are significantly different. The rate of posi-
tive findings in the neuropathy clinic group [12,13] are
similar to the high detection rates documented in the
literature [6,7,9], whereas the frequencies found in diag-
nostic laboratories are lower as shown in this and other
studies [13, Table 3].
Interestingly, in patients for whom NCS were lacking
we obtained a mutation detection rate of 16.5%, similar
to the detection rate found in the patient material as a
whole (16.6%). This demonstrates that the lack of NCS
results should not be used as an absolute exclusion cri-
terion for genetic testing. However, the laboratory of-
fered a wider panel (for both demyelinating and axonal
CMT) in those who did not have NCS results specified,
hence spending more resources.
The association between age at onset and age at tes-
ting is loose. A strong rise in incoming samples from pa-
tients of high age, mainly due to a rise in the requested
tests for patients with axonal polyneuropathy, is asso-
ciated with an increased number of phenocopies with
axonal polyneuropathy of different genesis. Moreover, on
average 42.9% of the patients > 50 years at testing have a
negative or unspecified family history, further contri-
buting to this tendency. Age at onset is therefore one of
the most important parameters in the decision algo-
rithm. Unfortunately, age at onset was reported only in
52.6% of the cases presented here.
The majority (95.8%) of the positive molecular genetic
findings were either duplication of the PMP22 region or a
sequence variant in either one of the MPZ, GJB1 or
MFN2 genes. The present study strongly indicates that
none of the genes that have been reported elsewhere
to be involved in rare cases of CMT (LITAF/SIMPLE,
EGR2, PMP22, NEFL, GDAP1 and MPZ/MFN2 deletions/duplications) are commonly involved in CMT in the
Norwegian population. These results are in accordance
with other recent publications on the frequency of genetic
subtypes [12,13] stating that >90% of mutations in indi-
viduals with a positive genetic test are caused by PMP22,
GJB1, MFN2 and MPZ, and that “recessive mutations” are
rare. “Recessive mutations” in SH3TC2 have been reported
as a frequent cause of demyelinating CMT in some popu-
lations [25]. SH3TC2 was not a part of the gene panel
used in this study, but in a recent paper the frequency was
reported to be 0.3% in a large CMT cohort from the
United Kingdom [13].
Conclusion
We suggest a pragmatic two-tier approach to genetic
testing in CMT; the first tier should be used by referral
centres receiving blood or DNA samples, not patients.
Genetic tests in this setting should primarily be selected
on the basis of nerve conduction studies. Patients sho-
wing demyelinating or mixed polyneuropathy/interme-
diate nerve conduction velocities, and those in whom
the polyneuropathy type is uncertain, should be tested
with PMP22 MLPA and DNA sequencing of the MPZ
and GJB1 genes. In cases with documented axonal poly-
neuropathy DNA sequencing of MFN2, MPZ and GJB1
is recommended. A similar conclusion was recently
made, based on a study of a CMT population from the
UK [13]. Unless there is a clear clinical indication of
CMT and positive family history, fifty years at age of
onset seems an appropriate cut off age for which testing
should be rejected. Good clinical documentation is
increasing the probability of detecting disease causing
mutations. For cases with sparse clinical information,
limited genetic testing as suggested above should be car-
ried out provided that the requests come from expe-
rienced neurologists, geneticists or paediatricians. Tests
should be restricted to cases with classical CMT, with or
without additional features as described in the clinical
group 4.
The second tier should be based on interdisciplinary
investigation of patients at neuromuscular centres. Several
excellent algorithms exist for this purpose [11,12]. Po-
werful tools, like next generation sequencing (NGS), are
nowadays implemented in clinical practice and provide
possibilities for more efficient genetic diagnostic service to
patients with hereditary polyneuropathies [26]. Of note,
we did not analyse all genes known to be associated with
CMT. A broad scanning of CMT associated genes likely
would have increased the mutation detection rate. Patients
negative for mutations in PMP22, GJB1 and MPZ, and
patients with atypical CMT2, HSAN and HMN should be
subjected to extended analysis by NGS and prioritization
of the genes to be investigated should be based on detailed
studies of the phenotype.
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